Please provide your email address to receive an email when new articles are posted on . Acute and recurrent pericarditis require medical management to improve morbidity and quality of life. Aspirin, ...

(RTTNews) - Scilex Holding Co. (SCLX) announced that FDA has approved it request for the Orphan drug designation for colchicine for the treatment of pericarditis. Pericarditis is an inflammation of ...

Gloperba ® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. Pericarditis is an inflammation of the ...

Scilex Holding Company announced that the FDA has granted orphan drug designation for the oral liquid version of colchicine, branded as Gloperba®, for treating pericarditis, an inflammation of the ...

Scilex Holding said the Food and Drug Administration granted orphan drug designation for colchicine for the treatment of pericarditis. The company's Gloperba, licensed from Romeg Therapeutics, is a ...

Please provide your email address to receive an email when new articles are posted on . Secondary prevention of CVD with colchicine is a major focus for the cardiology community, especially after ...

WASHINGTON, March 30 (Reuters) - A drug that was used in the time of the pharaohs for rheumatism has proven highly effective in treating recurrent bouts of pericarditis, an inflammation of the sac ...

PHILADELPHIA, PA—Colchicine, given orally prior to PCI in an all-comers population, does not reduce procedure-related myocardial injury, but does appear to attenuate the inflammatory response, results ...

The earlier the anti-inflammatory drug colchicine is initiated after a myocardial infarction (MI) the greater the benefit, a new COLCOT analysis suggests. The parent trial was conducted in patients ...

PHILADELPHIA -- A low oral dose of gout medication colchicine reduced ischemic events in heart attack survivors, the COLCOT trial showed, further affirming the inflammatory hypothesis. The potent anti ...